The Novel Role of Antibiotic Treatment in the Management of Cutaneous T-Cell Lymphoma (CTCL) Patients

Abstract

Keywords

cutaneous T-cell lymphoma (CTCL)signal transducer and activator of transcription (STAT)antibiotics treatment

Get full access to this article

View all access options for this article.

References

Lindahl

LM.

Willerslev-Olsen

Gjerdrum

LMR

et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134(13):1072-1083.doi:10.1182/blood.2018888107

http://www.ncbi.nlm.nih.gov/pubmed/31331920

Van-de-Velde

Zhou

. Existing and emerging therapies for cutaneous T-cell lymphoma. J Cutan Med Surg. 2019;23(3):319-327.doi:10.1177/1203475419840629

http://www.ncbi.nlm.nih.gov/pubmed/30943788

Ghazawi

FM.

Netchiporouk

Rahme

et al. Distribution and clustering of cutaneous T-cell lymphoma (CTCL) cases in Canada during 1992 to 2010. J Cutan Med Surg. 2018;22(2):154-165.doi:10.1177/1203475417745825

http://www.ncbi.nlm.nih.gov/pubmed/29241349

Litvinov

IV.

Shtreis

Kobayashi

et al. Investigating potential exogenous tumor initiating and promoting factors for cutaneous T-cell lymphomas (CTCL), a rare skin malignancy. Oncoimmunology. 2016;5(7):e1175799 doi:10.1080/2162402X.2016.1175799

http://www.ncbi.nlm.nih.gov/pubmed/27622024

Woetmann

Lovato

Eriksen

et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood. 2007;109(8):3325-3332.doi:10.1182/blood-2006-04-017863

http://www.ncbi.nlm.nih.gov/pubmed/17179233